R

Ryvu Therapeutics SA
WSE:RVU

Watchlist Manager
Ryvu Therapeutics SA
WSE:RVU
Watchlist
Price: 46.65 PLN 0.97%
Market Cap: 1.1B PLN
Have any thoughts about
Ryvu Therapeutics SA?
Write Note

Ryvu Therapeutics SA
Selling, General & Administrative

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Ryvu Therapeutics SA
Selling, General & Administrative Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Selling, General & Administrative CAGR 3Y CAGR 5Y CAGR 10Y
R
Ryvu Therapeutics SA
WSE:RVU
Selling, General & Administrative
-zł158.4m
CAGR 3-Years
-38%
CAGR 5-Years
-29%
CAGR 10-Years
-26%
I
Inno-Gene SA
WSE:IGN
Selling, General & Administrative
-zł1.1m
CAGR 3-Years
18%
CAGR 5-Years
-2%
CAGR 10-Years
-1%
M
Medicofarma Biotech SA
WSE:MDB
Selling, General & Administrative
-zł731.4k
CAGR 3-Years
-27%
CAGR 5-Years
-20%
CAGR 10-Years
N/A
S
Selvita SA
WSE:SLV
Selling, General & Administrative
-zł148.1m
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Ryvu Therapeutics SA
Glance View

Market Cap
1.1B PLN
Industry
Life Sciences Tools & Services

Ryvu Therapeutics SA engages in the provision of products and solutions for the pharmaceutical and biotechnology industry. The company is headquartered in Krakow, Woj. Malopolskie and currently employs 186 full-time employees. The company went IPO on 2011-07-14. The firm is active in the pharmaceutical and biotechnology fields. The company operates through two business segments. The Innovative segment develops new drugs mainly for oncology and central nervous system diseases. The Services segment is engaged in the research and development activities, such as introducing substances on the market, client service and reducing the risk. The Company’s portfolio encompasses projects, including kinesis inhibitors platform, the platform of the metabolism for the cancer and epigenetic, among others. Ryvu Therapeutics SA is active in the domestic market and internationally, such as in the United States. The company operates through unit Ardigen SA and SORS Holdings Ltd.

RVU Intrinsic Value
39.7 PLN
Overvaluation 15%
Intrinsic Value
Price
R

See Also

What is Ryvu Therapeutics SA's Selling, General & Administrative?
Selling, General & Administrative
-158.4m PLN

Based on the financial report for Sep 30, 2024, Ryvu Therapeutics SA's Selling, General & Administrative amounts to -158.4m PLN.

What is Ryvu Therapeutics SA's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-26%

Over the last year, the Selling, General & Administrative growth was -37%. The average annual Selling, General & Administrative growth rates for Ryvu Therapeutics SA have been -38% over the past three years , -29% over the past five years , and -26% over the past ten years .

Back to Top